Literature DB >> 16529599

The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement.

Janine Campbell1, John F Seymour, Jane Matthews, Max Wolf, Janey Stone, Surender Juneja.   

Abstract

BACKGROUND: The prognostic significance of marrow involvement in diffuse large cell lymphoma (DLCL) is controversial. Factors that that have been reported to influence prognosis include the pattern and extent of marrow infiltration and histological discordance between the primary site and the bone marrow.
METHODS: Bone marrow biopsies from 172 patients with newly diagnosed DLCL entered in two consecutive trials of the Australasian Leukaemia and Lymphoma Group were analyzed. Progression-free (PFS) and overall survival (OS) were calculated according to the absence or presence of bone marrow involvement (BMI), the extent of lymphomatous infiltration and the presence of histological discordance between the primary site and the bone marrow.
RESULTS: Of 172 patients with DLCL accrued between 1982 and 1990, who were treated with CHOP or CHOP-like regimens, 47 (27%) demonstrated marrow involvement on examination of multiple levels. Seventy two percent (34/47) of patients had discordant marrow involvement (<50% large cells) and 28 had minimal (<10%) involvement; these latter patients with minimal marrow involvement (<10%) had similar PFS &amp; OS to the 113 patients without involvement. Within the group of 47 patients with marrow involvement, an increasing percentage of BM involvement was significantly associated with an increasing percentage of concordant histology and a decreasing PFS &amp; OS.
CONCLUSIONS: Minimal BMI, seen in the majority of patients with DLCL with marrow infiltration, appears not to influence the PFS &amp; OS. However, an increasing degree of marrow involvement is associated with an increasing component of large cells and a poorer prognosis in DLCL patients, independent of other risk factors.

Entities:  

Mesh:

Year:  2006        PMID: 16529599     DOI: 10.1111/j.1600-0609.2006.00644.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  30 in total

Review 1.  Discordant bone marrow involvement in non-Hodgkin lymphoma.

Authors:  Jennifer Brudno; Tamar Tadmor; Stefania Pittaluga; Alina Nicolae; Aaron Polliack; Kieron Dunleavy
Journal:  Blood       Date:  2015-12-17       Impact factor: 22.113

2.  Role of immunohistochemistry in staging diffuse large B-cell lymphoma (DLBCL).

Authors:  Dipti Talaulikar; Jane Esther Dahlstrom; Bruce Shadbolt; Amy Broomfield; Anne McDonald
Journal:  J Histochem Cytochem       Date:  2008-06-23       Impact factor: 2.479

3.  Nodular pattern of bone marrow infiltration: frequent finding in immunosuppression-related EBV-associated large B-cell lymphomas.

Authors:  Deborah W Sevilla; Erin M Weeden; Suzy Alexander; Vundavalli V Murty; Bachir Alobeid; Govind Bhagat
Journal:  Virchows Arch       Date:  2009-10-06       Impact factor: 4.064

4.  Bone marrow aspirate and biopsy: a pathologist's perspective. II. interpretation of the bone marrow aspirate and biopsy.

Authors:  Roger S Riley; David Williams; Micaela Ross; Shawn Zhao; Alden Chesney; Bradly D Clark; Jonathan M Ben-Ezra
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

5.  High Ki-67 expression in involved bone marrow predicts worse clinical outcome in diffuse large B cell lymphoma patients treated with R-CHOP therapy.

Authors:  Moo-Kon Song; Joo-Seop Chung; Je-Jung Lee; Deok-Hwan Yang; In-Suk Kim; Dong-Hoon Shin; Ho-Jin Shin
Journal:  Int J Hematol       Date:  2014-12-12       Impact factor: 2.490

6.  Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma.

Authors:  Yucai Wang; Brian K Link; Thomas E Witzig; Matthew J Maurer; Cristine Allmer; Rebecca L King; Andrew L Feldman; Thomas M Habermann; Stephen M Ansell; Susan L Slager; James R Cerhan; Grzegorz S Nowakowski
Journal:  Blood       Date:  2019-10-17       Impact factor: 22.113

7.  Synchronous diffuse large B-cell lymphoma and malignant clonal plasma cells in bone marrow as primary presentation: a diagnostic and therapeutic challenge.

Authors:  Ritesh Sachdev; Shalini Goel; Smeeta Gajendra; Nitin Sood
Journal:  J Clin Diagn Res       Date:  2015-04-01

Review 8.  Central nervous system prophylaxis in non-Hodgkin lymphoma: who, what, and when?

Authors:  Chan Yoon Cheah; John F Seymour
Journal:  Curr Oncol Rep       Date:  2015-06       Impact factor: 5.075

9.  Bone marrow involvement in diffuse large B-cell lymphoma: correlation between FDG-PET uptake and type of cellular infiltrate.

Authors:  Gaetano Paone; Emmanuel Itti; Corinne Haioun; Philippe Gaulard; Jehan Dupuis; Chieh Lin; Michel Meignan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-12-19       Impact factor: 9.236

Review 10.  Current role of FDG PET/CT in lymphoma.

Authors:  Lale Kostakoglu; Bruce D Cheson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-12       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.